1334411-79-8

Basic information

• Product Name: 4-broMo-2-(2,6-dichlorophenyl)-1H-iMidazo[4,5-c]pyridine
• Synonyms: 4-broMo-2-(2,6-dichlorophenyl)-1H-iMidazo[4,5-c]pyridine;4-BroMo-2-(2,6-dichlorophenyl)-3H-iMidazo[4,5-c]pyridine;2-[2,6-dichlorophenyl]-4-Bromo-2H-imidazo[4,5-c]pyridine
• CAS NO: 1334411-79-8
• Molecular Formula: C₁₂H₆BrCl₂N₃
• Molecular Weight: 343.00614
• Mol File: 1334411-79-8.mol

Chemical Properties

• Boiling Point: 536.6±60.0 °C(Predicted)
• Appearance: /
• Density: 1.770±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 8.65±0.40(Predicted)
• CAS DataBase Reference: 4-broMo-2-(2,6-dichlorophenyl)-1H-iMidazo[4,5-c]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-broMo-2-(2,6-dichlorophenyl)-1H-iMidazo[4,5-c]pyridine(1334411-79-8)
• EPA Substance Registry System: 4-broMo-2-(2,6-dichlorophenyl)-1H-iMidazo[4,5-c]pyridine(1334411-79-8)

Safety Data

• Hazardous Substances Data: 1334411-79-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
4-bromo-2-(2,6-dichlorophenyl)-1H-imidazo[4,5-c]pyridine is used as a potential active pharmaceutical ingredient for the development of new drugs, leveraging its biological activities, particularly its effects on the central nervous system and its antitumor properties.
Used in Organic Synthesis:
In the field of organic synthesis, 4-bromo-2-(2,6-dichlorophenyl)-1H-imidazo[4,5-c]pyridine serves as a key intermediate or building block for the preparation of other heterocyclic compounds, contributing to the synthesis of novel molecules with potential applications in various industries.
Used in Central Nervous System Research:
4-bromo-2-(2,6-dichlorophenyl)-1H-imidazo[4,5-c]pyridine is utilized in research aimed at understanding and potentially treating disorders of the central nervous system, given its demonstrated effects in this area, which could lead to the development of new therapeutic agents.
Used in Antitumor Research:
4-bromo-2-(2,6-dichlorophenyl)-1H-imidazo[4,5-c]pyridine is employed in antitumor research to explore its potential as a cancer treatment, examining how it may interact with tumor cells and contribute to inhibiting tumor growth and progression.

Upstream product

• 39217-08-8 2-chloropyridine-3,4-diamine 
• 50-30-6 2,6-dichlorobenzoic acid 
• 4659-45-4 2,6-Dichlorobenzoyl chloride 
• 83-38-5 2,6-dichlorobenzaldehyde 
• 1334411-81-2 4-chloro-2-(2,6-dichlorophenyl)-1H-imidazo[4,5-c]pyridine 
• 1334411-80-1 2-(2,6-dichlorophenyl)-1H-imidazo[4,5-c]pyridin-4-ol 

Downstream Products

• 1334411-89-0 C₁₃H₈BrCl₂N₃ 
• 1334411-91-4 C₁₃H₈BrCl₂N₃ 
• 1334407-17-8 1-(2-(2,6-dichlorophenyl)-3H-imidazo[4,5-c]pyridin-4-yl)-3-methylurea 
• 1334407-07-6 2-(2,6-dichlorophenyl)-N-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-4-amine 
• 1334407-09-8 2-(2,6-dichlorophenyl)-N-(1H-pyrazol-4-yl)-3H-imidazo[4,5-c]-pyridin-4-amine 
• 1334407-10-1 N-(6-chloropyrimidin-4-yl)-2-(2,6-dichlorophenyl)-3H-imidazo[4,5-c]pyridin-4-amine 
• 1334407-11-2 2-(2,6-dichlorophenyl)-N-(6-morpholinopyrimidin-4-yl)-3H-imidazo[4,5-c]pyridin-4-amine 
• 1334407-13-4 N-(2-(2,6-dichlorophenyl)-3H-imidazo[4,5-c]pyridin-4-yl)thiazole-5-carboxamide 
• 1334407-15-6 (1S,2S)-N-(2-(2,6-dichlorophenyl)-3H-imidazo[4,5-c]pyridin-4-yl)-2-fluorocyclopropanecarboxamide 
• 1334407-14-5 (1R,2R)-N-(2-(2,6-dichlorophenyl)-3H-imidazo[4,5-c]pyridin-4-yl)-2-fluorocyclopropanecarboxamide 
• 1334408-20-6 C₁₆H₁₂Cl₂N₄O 
• 1334407-18-9 N-(2-(2,6-dichlorophenyl)-1-methyl-1H-imidazo[4,5-c]pyridine-4-yl)cyclopropanecarboxamide 
• 1334407-19-0 N-(2-(2,6-dichlorophenyl)-3-methyl-3H-imidazo[4,5-c]pyridine-4-yl)cyclopropanecarboxamide 

Relevant articles and documents

Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model

Herein we report identification of an imidazopyridine class of potent and selective TYK2 inhibitors, exemplified by prototype 6, through constraint of the rotatable amide bond connecting the pyridine and aryl rings of compound 1. Further optimization led to generation of compound 30 that potently inhibits the TYK2 enzyme and the IL-23 pathway in cells, exhibits selectivity against cellular JAK2 activity, and has good pharmacokinetic properties. In mice, compound 30 demonstrated dose-dependent reduction of IL-17 production in a PK/PD model as well as in an imiquimod-induced psoriasis model. In this efficacy model, the IL-17 decrease was accompanied by a reduction of ear thickness indicating the potential of TYK2 inhibition as a therapeutic approach for psoriasis patients.

IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

The invention provides compounds of Formulas Ia-Ib, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4, R5 and R16 are defined herein, a pharmaceutical composition that includes a compound of Formulas Ia-Ib and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of using the compound or composition in therapy.